Hypothesis: Variations in the deiodinase 2 gene and monocarboxylate transporter 10 gene is associated with improvement in quality of life after initiation of combination therapy with L-Thyroxine and Liothyronine in patients with persistent hypothyroid symptoms despite conventional L-thyroxine mono-therapy. Purpose: To re-test this hypothesis in patients with continued perceived effect of Liothyronine treatment at least one year after initiation in a patient population more representing of daily clinical practice. The study will help determine whether testing of specific gene variations might predict longtime effect of combination therapy.
Study Type
OBSERVATIONAL
Enrollment
82
Herlev Hospital
Herlev, Denmark
Polymorphisms in DIO2/MCT10 and triiodothyronine treatment
Group 1(responders) and group 2(non-responders) are compared with regard to polymorphisms in the DIO2 gene and the MCT10 gene. Polymorphisms will be determined from DNA in a blood sample
Time frame: Single assessment point, from 1-10 years after initiation of combination therapy
Proportion treated with triiodothyronine
How many patients are treated with triiodothyronine at least one year after initiation of combination therapy.
Time frame: Single assessment point, from 1-10 years after initiation of combination therapy
Quality of life questionnaire
Patients are scored on the ThyPRO questionnaire and a hypothyroid symptoms questionnaire.
Time frame: Single assessment point, from 1-10 years after initiation of combination therapy
Who controls the treatment?
Patients report whether treatment is controlled by 1) a general practitioner 2) Patient self 3) other type of healthcare professional 4) a certified endocrinologist or 5) other
Time frame: Single assessment point, from 1-10 years after initiation of combination therapy
How is current treatment controlled?
Patients report if current treatment is for example controlled by using blood samples or only on the basis of symptoms.
Time frame: Single assessment point, from 1-10 years after initiation of combination therapy
Have therapy changed after the patient left the department of endocrinology?
Current hypothyroidism treatment and doses of medication
Time frame: Single assessment point, from 1-10 years after initiation of combination therapy
TSH
Is the patient well regulated? Normal TSH: 0.1-4.0 (depending on assay used). Over-treatment: TSH \< 0.1 (depending on assay used). Under-treatment: TSH\>4 (depending on assay used).
Time frame: Single assessment point, from 1-10 years after initiation of combination therapy
Osteoporosis
DXA-scan
Time frame: Single assessment point, from 1-10 years after initiation of combination therapy
Risk of arrhythmia
Puls and blood pressure is measured. If arrhythmia is suspected, an ECG is performed.
Time frame: Single assessment point, from 1-10 years after initiation of combination therapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.